Literature DB >> 19892894

Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management.

K Wu1, M Politis, P Piccini.   

Abstract

Impulse control disorders (ICDs) are a heterogeneous group of conditions involving repetitive, excessive and compulsive activities that interfere with life functioning. Examples are pathological gambling, compulsive shopping and hypersexuality. Over the last decade, ICDs have become increasingly recognised as being associated with Parkinson disease (PD), with the literature highlighting a link between dopamine replacement therapy and the development of ICDs. Patients who develop ICDs in the context of compulsive anti-Parkinsonian drug use are described as having dopamine dysregulation syndrome (DDS), which is associated with repetitive complex stereotyped behaviours called punding. Case-control and observational studies have further noted that patients with PD who develop ICDs are more likely to have younger-onset PD, a history of alcohol dependence, novelty-seeking personality traits and psychiatric comorbidities. The pathophysiology of underlying mechanisms is not fully understood, but recent evidence suggests that dopaminergic drugs, particularly dopamine agonists, coupled with changes in reward pathways involving the ventral striatal and related circuitry, may play a role. Neuroimaging studies using positron emission tomography and functional MRI have provided valuable information in this area: patients with DDS have been found to show enhanced dopamine release in the ventral striatum, suggesting functional abnormalities in the mesolimbic networks. Management of ICDs in patients with PD can be challenging, as they may not be aware of a change in their behaviour or may conceal their symptoms to avoid embarrassment. Currently, there is no clear evidence of an optimal treatment. Management is based on a careful balance of dopaminergic drugs with control of the aberrant behaviour, supported by psychological interventions. This review aims to summarise the current literature on ICDs, their phenomenology, epidemiology, clinical features, pathophysiology and management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892894     DOI: 10.1136/pgmj.2008.075820

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  21 in total

1.  The Influence of Bilateral Subthalamic Nucleus Deep Brain Stimulation on Impulsivity and Prepulse Inhibition in Parkinson's Disease Patients.

Authors:  Lucy Gee; Heather Smith; Priscilla De La Cruz; Joannalee Campbell; Chris Fama; Jessica Haller; Adolfo Ramirez-Zamora; Jennifer Durphy; Era Hanspal; Eric Molho; Anne Barba; Damian Shin; Julie G Pilitsis
Journal:  Stereotact Funct Neurosurg       Date:  2015-06-10       Impact factor: 1.875

Review 2.  Psychiatric and Cognitive Effects of Deep Brain Stimulation for Parkinson's Disease.

Authors:  Adam Nassery; Christina A Palmese; Harini Sarva; Mark Groves; Joan Miravite; Brian Harris Kopell
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

3.  NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation.

Authors:  Jing-Si Zhou; Zhou Zhu; Feng Wu; Ying Zhou; Rui Sheng; Jun-Chao Wu; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

4.  Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-09

Review 5.  Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?

Authors:  Michael S Okun; Daniel Weintraub
Journal:  Mov Disord       Date:  2013-11-15       Impact factor: 10.338

Review 6.  Neuroimaging in Parkinson disease: from research setting to clinical practice.

Authors:  Marios Politis
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

7.  Acetaldehyde and parkinsonism: role of CYP450 2E1.

Authors:  Francesca Vaglini; Cristina Viaggi; Valentina Piro; Carla Pardini; Claudio Gerace; Marco Scarselli; Giovanni Umberto Corsini
Journal:  Front Behav Neurosci       Date:  2013-06-21       Impact factor: 3.558

8.  Dopaminergic and clinical correlates of pathological gambling in Parkinson's disease: a case report.

Authors:  Mette Buhl Callesen; K V Hansen; A Gjedde; J Linnet; A Møller
Journal:  Front Behav Neurosci       Date:  2013-07-29       Impact factor: 3.558

Review 9.  Parkinson's Disease, Religion, and Spirituality.

Authors:  Clare Redfern; Alasdair Coles
Journal:  Mov Disord Clin Pract       Date:  2015-07-15

10.  Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders.

Authors:  Clelia Pellicano; Flavia Niccolini; Kit Wu; Sean S O'Sullivan; Andrew D Lawrence; Andrew J Lees; Paola Piccini; Marios Politis
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.